Procter & Gamble reported weak fiscal year 2026 results with only 1% organic sales and core earnings per share growth. The company forecasts modest 1–3% organic sales growth for fiscal year 2027 amid challenges from rising private label competition, cost pressures, and a significant $1 billion after-tax headwind. Despite these issues, P&G maintains strong free cash flow and a roughly 3% dividend yield. The recent $3.8 billion acquisition of Thorne aims to diversify growth but carries risks due to the premium paid. Overall, the current share price reflects fair value amid growing macroeconomic uncertainty, leading analysts to maintain a Hold rating.
Procter & Gamble's stock rose nearly 6% following its Q1 2027 earnings report, which surpassed market expectations and included a modest increase in its full-year outlook. The company benefits from improving operating leverage as certain business uni...
Procter & Gamble reported fiscal Q1 adjusted earnings of $2.00 per share and revenue of $23.28 billion, surpassing analysts' expectations. The growth was driven by strong consumer demand for household and personal care products, especially laundry de...
Procter & Gamble's stock surged 6% following a quarterly earnings beat with core EPS of $2 and net sales of $23.28 billion, surpassing expectations. The company’s price increases are holding up well, driven by resilient higher-income consumers, thoug...
The BBB National Programs' National Advertising Division recommended Oral Essentials discontinue its claim that Lumineux Whitening Strips whiten teeth in 30 minutes. This followed a challenge by Procter & Gamble and a review of new studies submitted ...
Procter & Gamble reported first-quarter revenue of $23.28 billion, surpassing analyst expectations of $22.79 billion, driven by a 4% rise in organic sales across its product portfolio. Adjusted earnings per share reached $2, beating the $1.88 estimat...
